-
Distribution of class 1.1 new drugs in China
Time of Update: 2014-08-11
In order to get rid of the embarrassing situation of over dependence on imported original research drugs in the domestic market, in recent years, the government has vigorously supported drug research
-
Development of anti Ebola drugs and vaccines is imminent
Time of Update: 2014-08-11
In the past month, the epidemic of Ebola virus is still spreading in West Africa, which has attracted worldwide attention According to the World Health Organization, as of August 6, the number of case
-
Latest data of new drug approval in the first half of 2014
Time of Update: 2014-08-11
At the same time, the drug review center (CDE) of the State Food and drug administration undertook 4551 new drug registration applications in the first half of 2014 (based on the acceptance number), a
-
Advanced biological long-term treatment of HIV original new drug ibowetai phase 3 clinical trial is progressing smoothly
Time of Update: 2014-08-10
Xie Dong, male, chairman and chief technology officer of Chongqing frontier Biotechnology Co., Ltd., Ph.D and postdoctoral of Johns Hopkins University Former executive director of biomass heat center
-
Rongchang biology won nearly 35 million fund support for 2014 national major new drug creation technology major special project
Time of Update: 2014-08-05
In recent years, Rongchang biology attaches great importance to scientific and technological innovation It has successively introduced high-end scientific and technological talents such as Professor
-
The application for clinical application of the 3.1-class chemical drugs of HISCO, tolfatipu citrate and retamolin ointment, has been accepted
Time of Update: 2014-08-04
Tuofatipu citrate tablets (also known as tuofatipi citrate) belong to anti rheumatoid drugs Developed by Pfizer, it was listed in the United States for the first time on November 6, 2012, and listed c
-
Yatai group cooperates with wilkell pharmaceutical to research new drugs and imitation projects such as Viagra and vcp-2
Time of Update: 2014-08-01
After years of development, the pharmaceutical industry of Yatai group now has a pharmaceutical R & D center, three manufacturing enterprises and a pharmaceutical chain retail enterprise, forming a co
-
The first class new drug of Huashen group, ricatin, was selected into the clinical practice guide for liver transplantation of liver cancer in China (2014 Edition)
Time of Update: 2014-08-01
According to the introduction, the "practice guide" formulated by experts from organ transplantation branch of Chinese Medical Association, transplantation group of branch of external science of Chine
-
Approval of the first domestic "Viagra" Baiyunshan "Jinge"
Time of Update: 2014-08-01
According to the description on CFDA administrative Acceptance Center website, "approval completed - Certificate to be prepared" means that CFDA administrative acceptance service center is in the proc
-
Shenbai Shuxin capsule of Kaiyuan pharmaceutical, a subsidiary of Zhendong pharmaceutical, is about to obtain the production approval
Time of Update: 2014-08-01
According to the information released by the State Food and Drug Administration on August 1, the evaluation status of shenbaishuxin capsule, a traditional Chinese medicine variety of Kaiyuan pharmaceu
-
Baiyunshan "domestic Viagra" is named as Jinge
Time of Update: 2014-07-30
At the same time, Li Chuyuan said on his microblog that this is a great success of Baiyunshan's scientific and technological innovation and a sign of Baiyunshan's transformation and upgrading from mar
-
The first Chinese medicine Qingfei Sanjie pill for lung cancer
Time of Update: 2014-07-28
This is the first Chinese patent medicine recognized as having therapeutic effect in the field of cancer treatment According to a person in charge of Hainan Institute of drug control, with the impleme
-
4 new drugs of natural medicine: citrus fruit rheumatism analgesic gel paste (Babu agent) applied for clinical acceptance
Time of Update: 2014-07-24
Citrus spinosa is a typical desert medicinal plant, which grows mainly in gravelly slopes It is a folk medicine of Uygur nationality in Xinjiang Because of the traditional medicinal root bark, the lon
-
CFDA drug clinical approval in the first half of 2014
Time of Update: 2014-07-24
According to the statistics of Insight China Pharma data database of dingxiangyuan, in the first half of the year, CFDA approved a total of 314 drug clinical applications (calculated by acceptance num
-
CFDA drug listing approval in the first half of 2014
Time of Update: 2014-07-24
In the first half of 2014, compared with the same period of the past two years, the number of CFDA drugs approved for listing has decreased, and the number of traditional Chinese medicine and biologic
-
The price of Zhengda Tianqing dasatinib is only 1 / 8 of the original research drug, and the import substitution is also expected to accelerate
Time of Update: 2014-07-24
In April and June, Zhengda Tianqing dashatini was successively incorporated into the record procurement of Shandong and Hubei Province The price of 50mg specification was 70 yuan / tablet and 20mg spe
-
Zoelli pharmaceutical's new Chinese medicine "Lingze tablet" project will receive 10.42 million yuan of state funding subsidy
Time of Update: 2014-07-16
Zoelli pharmaceutical In the evening of July 15, it was announced that recently, the company received the notice on Forwarding the investment plan within the central budget of 2014 issued by the Minis
-
The first loss in half a year
Time of Update: 2014-07-12
In the evening of July 11, Laimei Pharmaceutical Co., Ltd released the semi annual performance forecast of 2014 It is estimated that from January to June, the company will lose 22 million yuan to 27 m
-
New drug research and development of Shuanglu pharmaceutical industry focuses on aging related varieties
Time of Update: 2014-06-25
Liang Shujie, board secretary of Shuanglu pharmaceutical Liang Shujie introduced in detail the progress of the company's reserve varieties: it is expected that the new dosage form will be produced in
-
Hengrui Pharmaceutical's anti-cancer drug oxaliplatin passed FDA certification
Time of Update: 2014-06-24
Oxaliplatin for injection is one of the main products of Hengrui medicine, which is mainly used for the first-line treatment of metastatic colorectal cancer and the adjuvant treatment of stage III col
